EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice

Ian R Woodcock iD, George Tachas, Nuket Desem, Peter J Houweling, Michael Kean, Jaiman Emmanuel, Rachel Kennedy iD, Kate Carroll, Katy de Valle, Justine Adams, Shireen R Lamandé, Chantal Coles und 9 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0294847 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift PLOS ONE, 2024. Verfasst von Ian R Woodcock und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Royal Children's Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Antisense Therapeutics Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ATL1102 is a 2’MOE gapmer antisense oligonucleotide to the CD49d alpha subunit of VLA-4, inhibiting expression of CD49d on lymphocytes, reducing survival, activation and migration to sites of inflammation. Children with DMD have dystrophin deficient muscles susceptible to contraction induced injury, which triggers the immune system, exacerbating muscle damage. CD49d is a biomarker of disease severity in DMD, with increased numbers of high CD49d expressing T cells correlating with more severe and progressive weakess, despite corticosteroid treatment.

Methods

This Phase 2 open label study assessed the safety, efficacy and pharmacokinetic profile of ATL1102 administered as 25 mg weekly by subcutaneous injection for 24 weeks in 9 non-ambulatory boys with DMD aged 10–18 years. The main objective was to assess safety and tolerability of ATL1102. Secondary objectives included the effect of ATL1102 on lymphocyte numbers in the blood, functional changes in upper limb function as assessed by Performance of Upper Limb test (PUL 2.0) and upper limb strength using MyoGrip and MyoPinch compared to baseline.

Results

Eight out of nine participants were on a stable dose of corticosteroids. ATL1102 was generally safe and well tolerated. No serious adverse events were reported. There were no participant withdrawals from the study. The most commonly reported adverse events were injection site erythema and skin discoloration. There was no statistically significant change in lymphocyte count from baseline to week 8, 12 or 24 of dosing however, the CD3+CD49d+ T lymphocytes were statistically significantly higher at week 28 compared to week 24, four weeks past the last dose (mean change 0.40x10 9 /L 95%CI 0.05, 0.74; p = 0.030). Functional muscle strength, as measured by the PUL2.0, EK2 and Myoset grip and pinch measures, and MRI fat fraction of the forearm muscles were stable throughout the trial period.

Conclusion

ATL1102, a novel antisense drug being developed for the treatment of inflammation that exacerbates muscle fibre damage in DMD, appears to be safe and well tolerated in non-ambulant boys with DMD. The apparent stabilisation observed on multiple muscle disease progression parameters assessed over the study duration support the continued development of ATL1102 for the treatment of DMD.

Trial registration

Clinical Trial Registration . Australian New Zealand Clinical Trials Registry Number: ACTRN12618000970246 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMaleChildAnimalsMiceHumansMice, Inbred mdxAustraliaMuscle, SkeletalAdrenal Cortex HormonesInflammation

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Neurology, The Royal Children's Hospital, Melbourne, Australia.
  • The Murdoch Children's Research Institute, Melbourne, Australia.
  • Department of Paediatrics, University of Melbourne, Melbourne, Australia.
  • Antisense Therapeutics Ltd, Melbourne, Australia.
  • Department of Medical Imaging, The Royal Children's Hospital, Melbourne, Australia.
  • Department of Physiotherapy, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Ian R Woodcock, Rachel Kennedy

Förderung

  • Antisense Therapeutics Ltd

Zitieren

APA

Woodcock, I. R., Tachas, G., Desem, N., Houweling, P. J., Kean, M., Emmanuel, J., Kennedy, R., Carroll, K., de Valle, K., Adams, J., Lamandé, S. R., Coles, C., Tiong, C., Burton, M., Villano, D., Button, P., Hogrel, J. Y., Catling-Seyffer, S., Ryan, M. M., …, & Yiu, E. M. (2024). A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0294847

Vancouver

Woodcock IR, Tachas G, Desem N, Houweling PJ, Kean M, Emmanuel J, et al. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice. PLOS ONE. 2024. doi:10.1371/journal.pone.0294847

BibTeX
@article{Woodcock2024,
  author = {Woodcock, Ian R and Tachas, George and Desem, Nuket and Houweling, Peter J and Kean, Michael and Emmanuel, Jaiman and Kennedy, Rachel and Carroll, Kate and de Valle, Katy and Adams, Justine and Lamandé, Shireen R and Coles, Chantal and Tiong, Chrystal and Burton, Matthew and Villano, Daniella and Button, Peter and Hogrel, Jean-Yves and Catling-Seyffer, Sarah and Ryan, Monique M and Delatycki, Martin B and Yiu, Eppie M},
  title = {A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0294847}
}
Kostenlos starten →